厄贝沙坦联合重组人脑利钠肽治疗充血性心力衰竭的临床疗效及安全性评价

Clinical efficacy and safety of Irbesartan combined with recombinant human brain natriuretic peptide in the treatment of congestive heart failure

目的探究对充血性心力衰竭患者应用厄贝沙坦联合重组人脑利钠肽治疗的临床诊治结果及安全性。方法选取2015年6月～2016年11月略阳县人民医院收治的充血性心力衰竭病症患者98例，随机分为对照组和观察组，每组49例。对照组患者给予厄贝沙坦，观察组在对照组用药基础上增加应用人脑利钠肽。结果观察组治疗有效率为95.92%，对照组对应数值83.67%（P＜0.05）；2组患者抗利尿激素、内皮素-1及血清去甲肾上腺素相较于治疗前均呈现显著下降趋势（P＜0.05）；观察组患者抗利尿激素、内皮素-1及血清去甲肾上腺素相较于对照组显著下降趋势（P＜0.05）；观察组不良反应发生率相较于对照组比较，差异无统计学意义。结论对充血性心力衰竭患者应用厄贝沙坦联合重组人脑利钠肽治疗方式实施救治有效性、安全性均较优。

Objective To investigate the clinical treatment and safety of Irbesartan combined with recombinant human brain natriuretic peptide in patients with congestive heart failure.Methods A total of98patients with congestive heart failure were enrolled in this study from June2015to November2016in Lueyang County People's Hospital.They were randomly divided into control group and observation group,49cases in each group.The control group was given Irbesartan,and the observation group was added with human brain natriuretic peptide on the basis of the control group.Results The effective rate of the observation group was95.92%,the control group was83.67%,and there was significant difference between two groups(P<0.05);the level of the antidiuretic hormone and endothelin-1and serum norepinephrine of the two groups were significantly decrease than before treatment(P<0.05);antidiuretic hormone and endothelin-1and serum norepinephrine epinephrine of patients in the observation group were decreased significantly compared with the control group(P<0.05);there was no statistical significance in adverse reaction rate between the observation group and the control group.Conclusion The treatment of Irbesartan combined with recombinant human brain natriuretic peptide in patients with congestive heart failure is effective and safe.